These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 21680571)

  • 1. Treatments for macular degeneration: summarising evidence using network meta-analysis.
    Fadda V; Maratea D; Trippoli S; Messori A
    Br J Ophthalmol; 2011 Oct; 95(10):1476-7. PubMed ID: 21680571
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative effectiveness.
    Brown G
    Curr Opin Ophthalmol; 2008 May; 19(3):175-6. PubMed ID: 18408489
    [No Abstract]   [Full Text] [Related]  

  • 3. CATT: Into the eye of a tiger.
    Sears J; Bena J; Singh AD
    Br J Ophthalmol; 2011 Jun; 95(6):761. PubMed ID: 21602481
    [No Abstract]   [Full Text] [Related]  

  • 4. Bevacizumab: a new way of doing business?
    Canning C; Lotery A
    Eye (Lond); 2006 Sep; 20(9):985-7. PubMed ID: 16858443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Some ethical considerations for the "off-label" use of drugs such as Avastin.
    Wong D; Kyle G
    Br J Ophthalmol; 2006 Oct; 90(10):1218-9. PubMed ID: 16980641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab: a new hope?
    Madhusudhana KC; Newsom RS
    Eye (Lond); 2009 Sep; 23(9):1755-7. PubMed ID: 19741717
    [No Abstract]   [Full Text] [Related]  

  • 7. Cheap shots and pricey propositions: evidence, disclosure, and treatment of age-related macular degeneration.
    Kimmelman J
    Retina; 2007; 27(9):1166-7. PubMed ID: 18046219
    [No Abstract]   [Full Text] [Related]  

  • 8. Avastin versus Lucentis: ethical issues in treatment of age-related macular degeneration.
    Klein RM; Klein RB
    Retina; 2007; 27(9):1163-5. PubMed ID: 18046218
    [No Abstract]   [Full Text] [Related]  

  • 9. Anti-VEGF for neovascular ARMD: visual improvement as the goal of therapy?
    Bopp S
    Br J Ophthalmol; 2007 Oct; 91(10):1259-60. PubMed ID: 17895411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Position paper: the need for head-to-head studies comparing Avastin versus Lucentis.
    Schmucker C; Antes G; Lelgemann M
    Surv Ophthalmol; 2009; 54(6):705-7. PubMed ID: 19818262
    [No Abstract]   [Full Text] [Related]  

  • 11. Avastin and new treatments for AMD: where are we?
    Freeman WR; Falkenstein I
    Retina; 2006 Oct; 26(8):853-8. PubMed ID: 17031283
    [No Abstract]   [Full Text] [Related]  

  • 12. Avastin versus Lucentis: ethical issues.
    Wong HC
    Retina; 2008; 28(7):1024-5; author reply 1025. PubMed ID: 18698312
    [No Abstract]   [Full Text] [Related]  

  • 13. [New drug treatment for age-related macular degeneration].
    Stefánsson E; la Cour M; Helgadóttir G; Sigurdsson H; Jónasson F
    Laeknabladid; 2007 Apr; 93(4):299-301. PubMed ID: 17460341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing ranibizumab with bevacizumab.
    Biswas P; Sengupta S; Choudhary R; Home S; Paul A; Sinha S
    Ophthalmology; 2011 Mar; 118(3):600-600.e2. PubMed ID: 21376243
    [No Abstract]   [Full Text] [Related]  

  • 15. Tachyphylaxis and bevacizumab.
    Avgikos KN; Horgan SE; Sivaraj RR; Hu K
    Ophthalmology; 2009 Sep; 116(9):1831-2; author reply 1832. PubMed ID: 19729101
    [No Abstract]   [Full Text] [Related]  

  • 16. Tachyphylaxis and bevacizumab.
    Ziemssen F; Neuhann IM; Voelker M
    Ophthalmology; 2009 Aug; 116(8):1591-2; author reply 1592-3. PubMed ID: 19651319
    [No Abstract]   [Full Text] [Related]  

  • 17. Radiation therapy for neovascular age-related macular degeneration revisited.
    Kim IK; Gragoudas ES
    Br J Ophthalmol; 2009 Mar; 93(3):279-80. PubMed ID: 19244026
    [No Abstract]   [Full Text] [Related]  

  • 18. Bevacizumab tachyphylaxis.
    Falavarjani KG; Modarres M
    Ophthalmology; 2009 May; 116(5):1016-7; author reply 1017. PubMed ID: 19410964
    [No Abstract]   [Full Text] [Related]  

  • 19. Intravitreal avastin: the low cost alternative to lucentis?
    Rosenfeld PJ
    Am J Ophthalmol; 2006 Jul; 142(1):141-3. PubMed ID: 16815262
    [No Abstract]   [Full Text] [Related]  

  • 20. New treatments for age-related macular degeneration.
    Avery RL
    Lancet; 2007 Oct; 370(9597):1479-80; author reply 1480. PubMed ID: 17964341
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.